The CASES-TCM study is a prospective, multicenter, observational study, which will enroll 20,000 patients with acute stroke (ischemic stroke or intracerebral hemorrhage) within 7 days of symptom onset. This study attempts to depict major clinical characteristics of acute stroke in patients with Chinese medicine treatment and to explore any difference compared with other non-Chinese medicine use cohorts and the effectiveness and safety of Chinese medicine.
Study Type
OBSERVATIONAL
Enrollment
20,000
Dongzhimen Hospital
Beijing, Beijing Municipality, China
Distribution of scores on the modified Rankin scale at 3-month follow-up
Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.
Time frame: 3 months follow-up
Recurrent stroke events (ischemic stroke, hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage) within 12-month follow-up
Number of patients with new ischemic stroke and hemorrhagic stroke within 12 months of follow-up.
Time frame: 12 months follow-up
Proportion of patients receive Chinese medicine treatment within 24 hours after admission
Chinese medicine treatment exposure defined as whether patients receive Chinese medicine injection, oral Chinese patent medicine, or compound Chinese medicine.
Time frame: 24 hours after admission
Chinese medicine treatment duration within 3-month, 12-month, and 24-month follow-up
Chinese medicine treatment duration will be assessed using proportion of days covered, which is a percentage of days covered with the medicine in the number of days the patient is eligible to have the medication.
Time frame: 3 months, 12 months, and 24 months follow-up
Change in the National Institutes of Health Stroke Scale score between baseline (admission) and discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
National Institute of Health Stroke Scale is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. It is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
Time frame: At admission (baseline) and discharge (14 days - mean for length of hospitalization for stroke patients)
Patient-Reported Outcomes Scale for Stroke score at discharge
Patient-Reported Outcomes Scale for Stroke, a structured questionnaire-scale was developed suitable for Chinese patients. The score ranges from 0 (best) to 144 (worst).
Time frame: At discharge (14 days - mean for length of hospitalization for stroke patients)
Proportion of patients with modified Rankin Scale score ≤2 at 3-month and 12-month follow-up
Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.
Time frame: 3 months, 12 months follow-up
Distribution of scores on the modified Rankin scale at 12-month follow-up
Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.
Time frame: 12 months follow-up
Proportion of patients with Barthel Index score ≥90 at 3-month and 12-month follow-up
Barthel Index is a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).
Time frame: 3 months, 12 months follow-up
Recurrent stroke events (ischemic stroke, hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage) within 3-month and 24-month follow-up
Number of patients with new ischemic stroke and hemorrhagic stroke events within 3 months and 24 months of follow-up.
Time frame: 3 months, 24 months follow-up
Composite of new clinical vascular events within 3-month, 12-month, and 24-month follow-up
Number of patients with new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ transient ischemic attack / myocardial infarction /vascular death) within 3 months, 12 months, and 24 months of follow-up.
Time frame: 3 months, 12 months, 24 months follow-up
Mini-Mental State Examination scale score at 3-month, 12-month, and 24-month follow-up
Mini-Mental State Examination scale is a commonly used scale for measuring the cognitive function. Range: 0 to 30 points, higher points represent a better outcome.
Time frame: 3 months, 12 months, 24 months follow-up
All-cause mortality within 12-month and 24-month follow-up
Number of patients who died within 12 months and 24 months of follow-up.
Time frame: 12 months, 24 months follow-up
Incidence of adverse events
Number of patients with any adverse events (including serious adverse events) during the study.
Time frame: Up to 24 months follow-up